News Bulletin
Monday, November 09, 2026
Morning Edition
Economic Numbers:
|
Time |
Event |
Actual |
Forecast |
Previous |
|
10:00 |
|
|
10756.00% |
|
|
10:00 |
|
|
1.80% |
|
|
10:00 |
|
0.006 |
0.60% |
|
|
10:30 |
|
0.034 |
3.40% |
|
|
11:00 |
|
|
3.90% |
|
|
11:30 |
|
|
4.04% |
|
|
11:30 |
|
|
4.15% |
|
|
13:00 |
|
|
4.93% |
Indices
|
|
CLOSE |
50 DMA |
200 DMA |
|
DJIA |
51,285.73 |
52,064.03 |
50,676.36 |
|
NASDAQ |
24,579.42 |
26,457.82 |
25,098.29 |
|
S&P 500 |
7,376.86 |
7,679.45 |
7,323.39 |
Earnings Calendar:
(EPS: Earning Per Share / Rev: Revenue / Mkt Cap : market Capital/ BMO :
Before Market Opening /AMC : After Market Close)
|
COMPANY |
EPS Act |
EPS
Fore |
Rev
Act |
Rev
Fore |
Mkt Cap |
Fiscal |
Time |
|
-/1.57 |
-/3.15B |
$91.31B |
Q3 |
AM |
|||
|
-/3.78 |
-/9.45B |
$81.66B |
Q3 |
AM |
|||
|
-/1.39 |
-/6.7B |
$47.70B |
Q3 |
PM |
|||
|
-/3.54 |
-/- |
$46.03B |
Q3 |
AM |
|||
|
-/0.95 |
-/1.75B |
$39.66B |
Q2 |
PM |
|||
|
-/3.19 |
-/8.95B |
$25.84B |
Q3 |
AM |
|||
|
-/1.93 |
-/353.13M |
$13.20B |
Q3 |
PM |
|||
|
-/1.13 |
-/2.19B |
$11.26B |
Q3 |
AM |
|||
|
-/8.07 |
-/615.72M |
$11.05B |
Q3 |
AM |
|||
|
-/0.29 |
-/806.3M |
$10.85B |
Q3 |
PM |
|||
|
-/- |
-/- |
$10.74B |
Q2 |
AM |
|||
|
-/2.88 |
-/3.52B |
$10.53B |
Q4 |
PM |
|||
|
-/8.08 |
-/1.48B |
$9.90B |
Q3 |
AM |
|||
|
-/-1.07 |
-/202.45M |
$8.04B |
Q3 |
AM |
|||
|
-/0.40 |
-/244.72M |
$7.63B |
Q3 |
AM |
|||
|
-/0.65 |
-/516.88M |
$7.14B |
Q3 |
AM |
|||
|
-/0.82 |
-/239.88M |
$7.07B |
Q3 |
AM |
|||
|
-/1.91 |
-/182.62M |
$7.01B |
Q3 |
PM |
|||
|
-/- |
-/- |
$6.71B |
Q3 |
PM |
|||
|
-/-1.36 |
-/209.74M |
$6.51B |
Q1 |
PM |
|||
|
-/0.47 |
-/550.71M |
$5.67B |
Q3 |
PM |
|||
|
-/1.17 |
-/391.78M |
$4.48B |
Q3 |
PM |
|||
|
-/0.90 |
-/1.57B |
$3.53B |
Q3 |
AM |
|||
|
-/1.19 |
-/71.77M |
$3.18B |
Q3 |
PM |
|||
|
-/-0.37 |
-/220.47M |
$2.91B |
Q3 |
PM |
|||
|
-/-2.25 |
-/583.17M |
$2.03B |
Q3 |
PM |
|||
|
-/0.58 |
-/1.16B |
$1.88B |
Q3 |
PM |
|||
|
$1.69B |
Q3 |
AM |
|||||
|
-/0.33 |
-/998.1M |
$1.58B |
Q3 |
PM |
|||
|
-/-0.07 |
-/203.73M |
$1.53B |
Q3 |
PM |
|||
|
-/6.49 |
-/187.05M |
$885.80M |
Q3 |
AM |
Market
News:
Here are some of the biggest premarket US stock movers today:
Vir Biotechnology, Inc. (NASDAQ: VIR) shares jumped
22% Monday after the company announced that its Phase 3 ECLIPSE 1 trial
evaluating elebsiran and tobevibart
in adults with chronic hepatitis delta met all primary and key secondary
endpoints.
QumulusAI (Nasdaq: QMLS)
has signed a five-year colocation agreement for 1.2
megawatts of critical IT load in Denver, with the capacity expected to be ready
for service in the first quarter of 2027, according to a press release from the
company.
The
Goodyear Tire & Rubber Company (GT) announced
that board member Roger Wood has been appointed interim chief executive
officer, effective immediately, as Mark Stewart steps down from the CEO and
president roles and from the board of directors.
Greenland Mines
Ltd (GRML) has increased its ownership in AnorTech
Inc. to approximately 19.9% after exercising an option to acquire additional
common shares, according to a press release issued under Canada’s early warning
reporting requirements.
KKR &
Co (NYSE: KKR) reported third quarter EPS of $1.78, $0.19 better
than the analyst estimate of $1.59. Revenue for the quarter came in at $4.56B
versus the consensus estimate of $2.69B.
Monday.com
(NASDAQ: MNDY) reported third-quarter results that exceeded
analyst expectations, but shares fell 7.3% as the company's guidance
disappointed investors.
Constellation
Energy (NASDAQ:CEG) shares advanced over 4% in premarket
trading on Monday after the U.S. nuclear and power producer beat third-quarter
profit expectations by a wide margin and raised the midpoint of its full-year
earnings forecast.
Spruce
Biosciences (Nasdaq: SPRB)
announced it has separated its CRHX-101 drug program into a newly formed
wholly-owned subsidiary called Adrenyx Biosciences,
Inc., with plans to distribute Adrenyx shares to
Spruce stockholders in the first half of 2027.
NRG (NYSE:
NRG) reported third quarter EPS of $4.68, $1.52 better
than the analyst estimate of $3.16. Revenue for the quarter came in at $9.5B
versus the consensus estimate of $9.33B.
Can-Fite BioPharma Ltd. (NYSE
American: CANF) announced that a patient with advanced liver cancer
who participated in a completed Phase II study of its drug Namodenoson
has reached ten years of overall survival, according to a press release issued
Nov. 9, 2026.
For internal use only